HTA5 Variation in Health Technology Assessments for Nivolumab Plus Chemotherapy Vs Chemotherapy in First-Line Gastric Cancer
Jun 1, 2023, 00:00 AM
10.1016/j.jval.2023.03.1434
https://www.valueinhealthjournal.com/article/S1098-3015(23)01534-6/fulltext
Section Title :
Section Order :
10835
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)01534-6&doi=10.1016/j.jval.2023.03.1434